Literature DB >> 10950049

Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis.

F A Rowe1, J H Walker, L C Karp, E A Vasiliauskas, S E Plevy, S R Targan.   

Abstract

OBJECTIVE: Cyclosporin-A (CSA) has been demonstrated to be effective for treatment of severe, steroid-resistant ulcerative colitis (UC). Use of CSA has been limited, however, because of low 1-yr response rates and the potential for complications. The aim of this study is to define clinical and laboratory factors predictive of response in severe, steroid-resistant UC.
METHODS: A retrospective review of 36 cases of severe, steroid-resistant UC treated with CSA was performed. Intravenous (i.v.) CSA was administered at an initial dose of 2.5 mg/kg, and oral (p.o.) CSA was given as twice the i.v. dose. Clinical response was recorded and logistic regression analysis was performed on clinical and laboratory factors for prediction of response to CSA.
RESULTS: Of 36 patients, 25 responded to i.v. CSA and were switched to p.o. CSA. Of the 25, 13 required colectomy by 9 months. The other 12 patients had a sustained response to CSA and avoided colectomy at 9 months. Overall, 24 of 36 patients treated with CSA required colectomy by 9 months. A high percentage of band neutrophils (bands) on admission was found to be a significant predictor of response to CSA.
CONCLUSIONS: Bands on admission are predictive of response to CSA and ultimately, the requirement for surgery in steroid-resistant UC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10950049     DOI: 10.1111/j.1572-0241.2000.02186.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  13 in total

1.  Choosing Therapy on the Basis of Disease Classifications in Inflammatory Bowel Disease.

Authors:  Maria T. Abreu
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06

Review 2.  Nasal manifestations of systemic illnesses.

Authors:  Isam Alobid; Jose Maria Guilemany; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2004-05       Impact factor: 4.806

3.  A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis.

Authors:  Atsushi Sakuraba; Toshiro Sato; Makoto Naganuma; Yuichi Morohoshi; Katsuyoshi Matsuoka; Nagamu Inoue; Hiromasa Takaishi; Haruhiko Ogata; Yasushi Iwao; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

Review 4.  Evolving medical therapies for ulcerative colitis.

Authors:  P Y Chung; R D Cohen
Journal:  Curr Gastroenterol Rep       Date:  2001-12

5.  Management of acute colitis and toxic megacolon.

Authors:  Scott A Strong
Journal:  Clin Colon Rectal Surg       Date:  2010-12

6.  Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy.

Authors:  Parita Patel; Andres Yarur; Sushila Dalal; Atsuhi Sakuraba; David T Rubin; Stephen B Hanauer; Ira Hanan; Laura H Raffals; Russell D Cohen; Joel Pekow
Journal:  Inflamm Bowel Dis       Date:  2018-05-18       Impact factor: 5.325

7.  Ulcerative colitis: steroid-refractory ulcerative colitis-ciclosporin or infliximab?

Authors:  Manreet Kaur; Stephen R Targan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-12-11       Impact factor: 46.802

Review 8.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

9.  Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis.

Authors:  Yasushi Umehara; Masatoshi Kudo; Masanori Kawasaki
Journal:  World J Gastroenterol       Date:  2008-09-14       Impact factor: 5.742

Review 10.  Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis.

Authors:  Takafumi Ando; Yuji Nishio; Osamu Watanabe; Hironao Takahashi; Osamu Maeda; Kazuhiro Ishiguro; Daisuke Ishikawa; Naoki Ohmiya; Yasumasa Niwa; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.